Circulating tumour DNA in blood is analysed to identify genomic features that distinguish early-stage lung cancer patients from risk-matched controls, and these are integrated into a machine-learning method for blood-based lung cancer screening.
Radiologic screening of high-risk adults reduces lung-cancer-related mortality(1,2)
